Limits...
The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case-control study.

Dong MJ, Wang LB, Jiang ZN, Jin M, Hu WX, Shen JG - Onco Targets Ther (2014)

Bottom Line: Receiver operating characteristic curve analysis showed that the patients with a histoscore of KLF4 expression >0.18 had a lower pCR rate.Multivariable analysis showed that higher KLF4 expression (odds ratio 0.013; 95% confidence interval 0.013-0.444; P=0.004) was independently correlated with a lower pCR rate after neoadjuvant chemotherapy.KLF4 overexpression was associated with lower pCR in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgical Oncology, Zhejiang University College of Medicine, Hangzhou, People's Republic of China.

ABSTRACT

Background: To identify whether a stem cell biomarker, KLF4, may predict the pathologic tumor response to neoadjuvant chemotherapy for patients with locally advanced breast cancer.

Methods: Twelve locally advanced breast cancer patients who achieved pathologic complete remission (pCR) after neoadjuvant chemotherapy were identified and for each, three non-pCR breast cancer patients - matched for age, clinical tumor-node-metastasis stage, and neoadjuvant chemotherapy cycles - were selected. The relationship between KLF4 expression in the core needle biopsied cancer tissue and patient pCR rate was assessed using univariate and multivariate analysis.

Results: Receiver operating characteristic curve analysis showed that the patients with a histoscore of KLF4 expression >0.18 had a lower pCR rate. Multivariable analysis showed that higher KLF4 expression (odds ratio 0.013; 95% confidence interval 0.013-0.444; P=0.004) was independently correlated with a lower pCR rate after neoadjuvant chemotherapy.

Conclusion: KLF4 overexpression was associated with lower pCR in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy. This study suggests that KLF4 may serve as a predictor for pCR in patients with breast cancer after neoadjuvant chemotherapy.

No MeSH data available.


Related in: MedlinePlus

Prognostic disease-free survival and overall survival analyses for locally advanced breast cancer patients who received neoadjuvant chemotherapy according to KLF4 expression.Notes: (A) Disease-free survival (DFS). (B) Overall survival (OS).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4216037&req=5

f3-ott-7-1963: Prognostic disease-free survival and overall survival analyses for locally advanced breast cancer patients who received neoadjuvant chemotherapy according to KLF4 expression.Notes: (A) Disease-free survival (DFS). (B) Overall survival (OS).

Mentions: The median survival duration in patients who had a tumor with low or high KLF4 expression was 78 months and 47 months, respectively. Elevated KLF4 expression was associated with inferior disease-free survival (P=0.044; Figure 3A), but KLF4 expression did not significantly contribute to overall survival (P=0.419; Figure 3B).


The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case-control study.

Dong MJ, Wang LB, Jiang ZN, Jin M, Hu WX, Shen JG - Onco Targets Ther (2014)

Prognostic disease-free survival and overall survival analyses for locally advanced breast cancer patients who received neoadjuvant chemotherapy according to KLF4 expression.Notes: (A) Disease-free survival (DFS). (B) Overall survival (OS).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4216037&req=5

f3-ott-7-1963: Prognostic disease-free survival and overall survival analyses for locally advanced breast cancer patients who received neoadjuvant chemotherapy according to KLF4 expression.Notes: (A) Disease-free survival (DFS). (B) Overall survival (OS).
Mentions: The median survival duration in patients who had a tumor with low or high KLF4 expression was 78 months and 47 months, respectively. Elevated KLF4 expression was associated with inferior disease-free survival (P=0.044; Figure 3A), but KLF4 expression did not significantly contribute to overall survival (P=0.419; Figure 3B).

Bottom Line: Receiver operating characteristic curve analysis showed that the patients with a histoscore of KLF4 expression >0.18 had a lower pCR rate.Multivariable analysis showed that higher KLF4 expression (odds ratio 0.013; 95% confidence interval 0.013-0.444; P=0.004) was independently correlated with a lower pCR rate after neoadjuvant chemotherapy.KLF4 overexpression was associated with lower pCR in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgical Oncology, Zhejiang University College of Medicine, Hangzhou, People's Republic of China.

ABSTRACT

Background: To identify whether a stem cell biomarker, KLF4, may predict the pathologic tumor response to neoadjuvant chemotherapy for patients with locally advanced breast cancer.

Methods: Twelve locally advanced breast cancer patients who achieved pathologic complete remission (pCR) after neoadjuvant chemotherapy were identified and for each, three non-pCR breast cancer patients - matched for age, clinical tumor-node-metastasis stage, and neoadjuvant chemotherapy cycles - were selected. The relationship between KLF4 expression in the core needle biopsied cancer tissue and patient pCR rate was assessed using univariate and multivariate analysis.

Results: Receiver operating characteristic curve analysis showed that the patients with a histoscore of KLF4 expression >0.18 had a lower pCR rate. Multivariable analysis showed that higher KLF4 expression (odds ratio 0.013; 95% confidence interval 0.013-0.444; P=0.004) was independently correlated with a lower pCR rate after neoadjuvant chemotherapy.

Conclusion: KLF4 overexpression was associated with lower pCR in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy. This study suggests that KLF4 may serve as a predictor for pCR in patients with breast cancer after neoadjuvant chemotherapy.

No MeSH data available.


Related in: MedlinePlus